From cross-border healthcare to pharmaceutical regulation, fiscal policies to COVID-19, global interactions to Brexit, the reach of European Union (EU) health law and policy continues to evolve, generating more and more questions about the role of the EU, effects on Member States and other countries’ healthcare systems, and interactions with entities as diverse as the Council of Europe, the European Court of Human Rights and the World Health Organization.
Health in Europe is…
A virtual discussion forum hosted by the Centre for Law and Society, Lancaster Law School (UK)
All discussions run between 12pm and 1pm (UK time) via Teams, unless otherwise indicated.
NB – you need to register via the links below to have access to the discussion! Teams invites will be sent to those who have registered approx. 24-48 hours before the event.
If you would like to attend, present, or be added to the mailing list, please email Dr Mary Guy (email@example.com).
Next Health in Europe discussion is….12pm (UK time) Wednesday 20th October 2021….
Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the EU
Dr Aurélie Mahalatchimy and Dr Éloïse Gennet
(MR 7318 DICE CERIC, CNRS- Aix-Marseille University)
The Covid-19 pandemic has highlighted many loopholes in how innovative pharmaceutical products are created, evaluated, produced and distributed in EU countries. One of the most visible issue brought into the spotlight has been and still is the gruelling lack of health equity, be it between EU citizens or between EU countries. Although the European Union has demonstrated unprecedented solidarity in response to the crisis, the new Pharmaceutical Strategy for Europe may be the opportunity to address some of these loopholes and strive for even more ambitious standards of equity of access to therapies.
While the EU’s pharmaceutical strategy has mainly been built on pursuing internal market objectives due to historical politico-legal reasons, a successful proposal for an EU Health Policy Platform 2021 Thematic network offers a contrast by promoting an inclusive and equitable European pharmaceutical strategy in reaffirming health as a fundamental value.
We will work on this proposal with interested health stakeholders of the EU Health Policy Platform through exploring:
- the evolution of the role of the European Commission and Directorate General for Health and Food Safety,
- Patient-centered approaches and inclusive research & development strategies, and
- Solidarity, trust and equitable access to pharmaceuticals.
Dr Aurélie Mahalatchimy and Dr Éloïse Gennet (UMR 7318 DICE CERIC, CNRS- Aix-Marseille University, France) on behalf of the European Association for Health Law (EAHL) Interest Group on Supranational Biolaw, join us to discuss the development of the Thematic Network proposal and ongoing work on this.
Wednesday 3rd November 2021Register here
Professor Markus Frischhut (MCI Innsbrück)
|EU law, common values and public health|
|December 2021 (date TBC)||Dr Tamara Popic (QMUL)||Health Politics in Europe|